Nxera Pharma Co., Ltd.
4565.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | ¥89,590 | ¥81,364 | ¥81,181 | ¥94,173 |
| - Cash | ¥28,461 | ¥32,997 | ¥34,465 | ¥32,268 |
| + Debt | ¥63,140 | ¥64,723 | ¥66,264 | ¥67,900 |
| Enterprise Value | ¥124,269 | ¥113,090 | ¥112,980 | ¥129,805 |
| Revenue | ¥6,754 | ¥8,450 | ¥6,644 | ¥6,852 |
| % Growth | -20.1% | 27.2% | -3% | – |
| Gross Profit | ¥4,081 | ¥6,592 | ¥5,029 | ¥4,725 |
| % Margin | 60.4% | 78% | 75.7% | 69% |
| EBITDA | -¥1,806 | ¥787 | -¥825 | -¥1,574 |
| % Margin | -26.7% | 9.3% | -12.4% | -23% |
| Net Income | -¥1,672 | -¥2,377 | -¥760 | -¥1,335 |
| % Margin | -24.8% | -28.1% | -11.4% | -19.5% |
| EPS Diluted | -18.48 | -26.38 | -8.45 | -14.85 |
| % Growth | 29.9% | -212.2% | 43.1% | – |
| Operating Cash Flow | -¥2,976 | -¥180 | ¥613 | -¥10,970 |
| Capital Expenditures | -¥102 | -¥90 | -¥109 | -¥153 |
| Free Cash Flow | -¥3,078 | -¥270 | ¥504 | -¥11,123 |